TY - JOUR
T1 - High-dose cytosine arabinoside in chronic lymphocytic leukemia
T2 - A clinical and pharmacologic analysis
AU - Robertson, L. E.
AU - Hall, Roy
AU - Keating, Michael J.
AU - Estey, Elihu
AU - Kantarjian, Hagop M.
AU - Mclaughlin, Peter
AU - Hagemeister, Frederick B.
AU - Plunkett, William
N1 - Funding Information:
Supported in part by grant CA32839 from the National Cancer Institute, DHHS.
PY - 1993
Y1 - 1993
N2 - Twenty-seven patients with B-cell chronic lymphocytic leukemia (CLL) or a related lymphoid malignancy were treated with high-dose cytosine arabinoside (ara-C) at a dosage of 3 gm/m2 administered over 2 hours every 12 hours at one to four doses per course, which were repeated at 4-week intervals. Median patient age was 60 years. Fifty-four percent of CLL patients had Rai stage III or IV disease and the median number of prior therapies was three. Two patients achieved a complete response, five had a partial response, and two had clinical improvement for an overall response rate of 33% The median duration of response was 9 months. Myelosuppression and infection were the main toxicities. Intracellular levels of the active metabolite ara-C triphosphate varied among patients, but comparisons of pharmacokinetic parameters revealed no significant differences between responders and non-responders. We conclude that high-dose ara-C has modest activity in CLL and that its use in combination with other agents in the treatment of CLL is warranted.
AB - Twenty-seven patients with B-cell chronic lymphocytic leukemia (CLL) or a related lymphoid malignancy were treated with high-dose cytosine arabinoside (ara-C) at a dosage of 3 gm/m2 administered over 2 hours every 12 hours at one to four doses per course, which were repeated at 4-week intervals. Median patient age was 60 years. Fifty-four percent of CLL patients had Rai stage III or IV disease and the median number of prior therapies was three. Two patients achieved a complete response, five had a partial response, and two had clinical improvement for an overall response rate of 33% The median duration of response was 9 months. Myelosuppression and infection were the main toxicities. Intracellular levels of the active metabolite ara-C triphosphate varied among patients, but comparisons of pharmacokinetic parameters revealed no significant differences between responders and non-responders. We conclude that high-dose ara-C has modest activity in CLL and that its use in combination with other agents in the treatment of CLL is warranted.
KW - CLL
KW - Cytosine arabinoside
UR - http://www.scopus.com/inward/record.url?scp=0027250333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027250333&partnerID=8YFLogxK
U2 - 10.3109/10428199309147355
DO - 10.3109/10428199309147355
M3 - Article
C2 - 8374522
AN - SCOPUS:0027250333
SN - 1042-8194
VL - 10
SP - 43
EP - 48
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1-2
ER -